Breast Cancer Clinical Trial
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
This is a first-in-human Phase 1/2, non-randomized, multi-centre, open-label clinical trial designed to investigate safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumour activity of [111In]-FPI-1547 Injection (radioimmuno-imaging agent) and [225Ac]-FPI-1434 Injection (radioimmuno-therapeutic) and to establish the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of repeat doses of [225Ac]-FPI-1434 Injection in patients with solid tumours that demonstrate uptake of [111In]-FPI-1547. The study consists of a Phase 1 portion that includes dose ascending cohorts (single and multi-dosing administration with/without cold antibody), a Cold Antibody Sub-Study, and a Phase 2 portion that includes tumour-specific cohorts.
This study consists of a Phase 1 portion and a Phase 2 portion.
Phase 1 includes the following cohorts: Single dose-ascending cohorts and Multi- dose ascending cohorts of [225Ac]-FPI-1434 and Multi- dose ascending cohorts evaluating administration of FPI-1175 (cold antibody), followed by, [225Ac]-FPI-1434 (cold + hot), with cycles repeating every 42 days. And Cold Antibody Sub-study evaluating administration of ascending doses of FPI-1175 followed by [111In]-FPI-1547.
The Phase 2 will evaluate [111In]-FPI-1547 and [225Ac]-FPI-1434 with or without FPI-1175 in tumour-specific cohorts. The decision to utilize FPI-1175 in the Phase 2 portion of the study will be determined based on Phase 1 data, including safety, tolerability, pharmacokinetic and dosimetry results.
Pathologically documented, definitively diagnosed, advanced solid tumour that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy.
Measurable or evaluable disease in accordance with RECIST 1.1.
Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
Life expectancy of greater than 3 months as judged by the treating physician.
Available tumour tissue (either archival or fresh biopsy) for IGF-1R immunohistochemistry. Submission of the tissue is not required prior to enrollment.
Adequate heart, kidney, and liver function
Adequate bone marrow reserves
Ability to understand and the willingness to sign a written informed consent document.
Phase 2 Specific
Histologically and/or cytologically documented diagnosis of locally advanced, inoperable, metastatic, or recurrent solid tumour types: endometrial, cervical, ovarian, TNBC, HER 2-negative breast, HNSCC, ACC, or uveal melanoma.
Have measurable disease per RECIST 1.1 Failure to respond to standard systemic therapy, or for whom standard or curative systemic therapy does not exist or is not tolerable.
Prior to the initial [225Ac]-FPI-1434 cycle: Sufficient target expression in at least 1 lesion following [111In]-FPI-1547 and SPECT imaging.
Systemic therapeutic radiopharmaceutical within 6 months prior to enrollment into this study.
Contraindications to or inability to perform the required imaging procedures in this study (e.g., inability to lay flat during scan time)
Uncontrolled brain metastasis, including but not limited to the need for treatment with steroids, surgery or radiation therapy.
Anticancer therapy (including investigational agents) or external beam radiation therapy within 14 days of the dosing of [111In]-FPI-1547
Has known additional malignancy that is progressing or has required active treatment within the past 3 years. Patients with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (e.g., breast cancer, cervical cancer, prostate) that have undergone potentially curative therapy are not excluded.
Residual CTCAE ≥ Grade 2 side effects of prior therapy, with the exception of residual grade 2 alopecia.
Prior organ transplantation, including stem cell transplantation.
Any prior treatment with nitrosoureas or actinomycin-D.
Clinically relevant levels of protein in the urine
Known or suspected allergies or contraindications to the Investigational Products or any component of the investigational drug formulation.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, diabetes, or psychiatric illness/social situations that would limit compliance with study requirements.
Received > 20 Gy prior radiation to large areas of the bone marrow
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
Duarte California, 91010, United States
Boston Massachusetts, 02215, United States
Minneapolis Minnesota, 55455, United States
Buffalo New York, 14203, United States
New York New York, 10065, United States
Philadelphia Pennsylvania, 19104, United States
Houston Texas, 77030, United States
Adelaide South Australia, 5000, Australia
Heidelberg Victoria, 3084, Australia
Hamilton Ontario, L8V 5, Canada
Toronto Ontario, M5G 2, Canada
Montréal Quebec, H2X 0, Canada
Québec City Quebec, G1R 2, Canada
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.